CVS won’t add Gilead’s HIV shot to drug coverage lists, Reuters reports

CVS Health (CVS) won’t add Gilead’s (GILD) new HIV prevention drug to its commercial plans for now, despite the medication’s proven effectiveness, a spokesperson tells Reuters, Deena Beasley reports. It also will not cover Yeztugo under its Affordable Care Act formularies, since its ACA preventive program follows recommendations and mandates from the U.S. Department of Health and Human Services. CVS based the decision on clinical, financial, and regulatory factors, spokesperson David Whitrap said in an email.